trending Market Intelligence /marketintelligence/en/news-insights/trending/oi9J3YxDdmEFxU3O6XjOhA2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Spring Bank halts mid-stage studies for hepatitis B drug

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Spring Bank halts mid-stage studies for hepatitis B drug

Spring Bank Pharmaceuticals Inc. stopped dosing and enrolling patients with chronic hepatitis B virus in its phase 2 trials evaluating the 400-milligram dose of inarigivir.

The Hopkinton, Mass.-based biotech in a Dec. 26 press release said that the decision is based on the laboratory observations of a specific phase 2 trial, dubbed Catalyst 2.

Findings from the tests showed evidence of liver dysfunction and a rise in alanine transaminase — an enzyme found in kidney and liver cells — consistent with liver injury in three patients with chronic HBV who were given a 400-milligram dose of inarigivir under the mid-stage study.

Additionally, given the findings, Spring Bank is evaluating the drug's safety in about 100 patients receiving inarigivir at this dose.

Spring Bank also said it will be working with the members of data safety monitoring board, clinical trial investigators and external experts regarding this specific drug dose to decide how to further its clinical development.

The 100-milligram dose of inarigivir has previously met its key goals of safety and antiviral activity in another mid-stage study evaluating patients with chronic HBV.